{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:06:03Z","timestamp":1773921963542,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001302.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,8,31]],"date-time":"2016-08-31T00:00:00Z","timestamp":1472601600000}}],"reference-count":85,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001302.pub3","type":"journal-article","created":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T11:24:18Z","timestamp":1472729058000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Volume expanders for the prevention of ovarian hyperstimulation syndrome"],"prefix":"10.1002","volume":"2016","author":[{"given":"MA","family":"Youssef","sequence":"first","affiliation":[{"name":"Faculty of Medicine, Cairo University; Department of Obstetrics & Gynaecology; Cairo Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selma","family":"Mourad","sequence":"additional","affiliation":[{"name":"Radboud University Medical Centre; Nijmegen Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,31]]},"reference":[{"issue":"11","key":"10.1002\/14651858.CD001302.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"2283-8","DOI":"10.1093\/humrep\/deg451","article-title":"Intravenous albumin does not prevent moderate-severe ovarian hyperstimulation syndrome in high-risk IVF patients: a randomized controlled study","volume":"18","author":"Bellver","year":"2003","journal-title":"Human Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD001302.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0301-2115(00)00452-8","article-title":"Intravenous albumin versus hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme: a prospective randomised placebo controlled study","volume":"96","author":"Gokmen","year":"2001","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/S0301-2115(95)02603-7","article-title":"Intravenous albumin prevents moderate-severe ovarian hyperstimulation in in vitro fertilisation patients: a prospective randomized and controlled study","volume":"70","author":"Isik","year":"1996","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"issue":"4","key":"10.1002\/14651858.CD001302.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.fertnstert.2006.11.170","article-title":"Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study","volume":"88","author":"Isikoglu","year":"2007","journal-title":"Fertility and Sterility"},{"issue":"7","key":"10.1002\/14651858.CD001302.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/humrep\/14.7.1920","article-title":"Does i.v albumin prevent ovarian hyperstimulation syndrome?","volume":"14","author":"Koike","year":"1999","journal-title":"Human Reproduction"},{"issue":"9","key":"10.1002\/14651858.CD001302.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1093\/humrep\/13.9.2421","article-title":"Prophylactic intravenous hydroxyethyle starch solution prevents moderate-severe ovarian hyperstimulation in in-vitro fertilization patients: a prospective, randomized, double-blind and placebo-controlled study","volume":"13","author":"Konig","year":"1998","journal-title":"Human Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD001302.pub3-BIB0007|cit7","first-page":"159","article-title":"Administration of mannitol to prevent severe ovarian hyperstimulation syndrome: A randomized controlled trial","volume":"8","author":"Saremi","year":"2003","journal-title":"Middle East Fertility Society Journal"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1093\/HUMREP\/10.6.1373","article-title":"Decreased incidence of severe ovarian hyperstimulation syndrome in high risk in-vitro fertilisation patients receiving intravenous albumin: a prospective study","volume":"10","author":"Shalev","year":"1995","journal-title":"Human Reproduction"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0015-0282(16)56829-0","article-title":"Intravenous albumin for the prevention of severe ovarian hyperstimulation syndrome in an invitro fertilisation program: a prospective, randomised, placebo-controlled study","volume":"62","author":"Shoham","year":"1994","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/S0015-0282(01)01784-8","article-title":"Hydroxyethyl starch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome: a preliminary report","volume":"75","author":"Abramov","year":"2001","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0011|cit11","first-page":"121","article-title":"Hydroxyethylstarch versus human albumin for the treatment of severe ovarian hyperstimulation syndrome","volume":"16","author":"Abramov","year":"2001","journal-title":"Fertility and Sterility. Abstracts of the 17th Annual meeting of the ESHRE"},{"issue":"4","key":"10.1002\/14651858.CD001302.pub3-BIB0012|cit12","first-page":"240","article-title":"The effectiveness of 6% hydroxyethyle starch solution in reducing the incidence of severe hyperstimulation syndrome in polycystic ovarian disease patients: A prospective cohort clinical trial","volume":"7","author":"Abuzeid","journal-title":"Journal of Reproductive Medicine and Endocrinology,"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0013|cit13","first-page":"S41-S42","article-title":"Cabergoline versus human albumin in prophylaxis ovarian hyperstimulation syndrome","volume":"Suppl. 3","author":"Ahmadi","year":"2010","journal-title":"Reproductive BioMedicine Online"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1093\/oxfordjournals.humrep.a138185","article-title":"The use of intravenous albumin in patients at high risk for severe ovarian hyperstimulation syndrome","volume":"8","author":"Asch","year":"1993","journal-title":"Human Reproduction"},{"issue":"9","key":"10.1002\/14651858.CD001302.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1093\/humrep\/16.9.1880","article-title":"The questionable use of albumin for the prevention of ovarian hyperstimulation syndrome in an IVF programme: a randomized placebo-controlled trial","volume":"16","author":"Ben Chetrit","year":"2001","journal-title":"Human Reproduction"},{"issue":"10","key":"10.1002\/14651858.CD001302.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1093\/oxfordjournals.humrep.a135784","article-title":"Intravenous albumin and the prevention of severe ovarian hyperstimulation syndrome","volume":"10","author":"Ben-Rafael","year":"1995","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0017|cit17","first-page":"315","article-title":"Oral whey protein for preventing ovarian hyperstimulation syndrome","volume":"84","author":"Cambiaghi","journal-title":"Fertility and Sterility. Abstracts from the annual meeting of ASRM"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0015-0282(97)81517-8","article-title":"Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome","volume":"68","author":"Chen","year":"1997","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/S0015-0282(03)00548-X","article-title":"Comparison of coasting and intravenous albumin in the prevention of ovarian hyperstimulation syndrome","volume":"80","author":"Chen","year":"2003","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD001302.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000010306","article-title":"Use of intramuscular progesterone versus intravenous albumin for the prevention of ovarian hyperstimulation syndrome","volume":"50","author":"Costabile","year":"2000","journal-title":"Gynecologic and Obstetric Investigation"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0021|cit21","first-page":"S41-S42","article-title":"Comparison of calcium gluconate and starch solution in the treatment of ovarian hyperstimulation syndrome","volume":"3","author":"Dmitrieva","year":"2010","journal-title":"Reproductive BioMedicine Online"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1093\/humrep\/12.12.2603","article-title":"Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotrophin for the prevention of severe ovarian hyperstimulation syndrome in invitro fertilisation: a prospective randomised study","volume":"12","author":"Egbase","year":"1997","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.fertnstert.2014.09.046","article-title":"Calcium infusion for the prevention of ovarian hyperstimulation syndrome: a double-blind randomized controlled trial","volume":"103","author":"El-Khayat","year":"2015","journal-title":"Fertility and Sterility"},{"issue":"5","key":"10.1002\/14651858.CD001302.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.fertnstert.2004.04.045","article-title":"Low-molecular-weight dextran infusion is more effective for the treatment of hemoconcentration due to severe ovarian hyperstimulation syndrome than human albumin infusion","volume":"82","author":"Endo","year":"2004","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0025|cit25","first-page":"34","article-title":"Assisted reproductive Intravenous hydroxyethyl starch versus human albumin for prevention of the ovarian hyperstimulation syndrome","volume":"2","author":"Fan","year":"2006","journal-title":"VIII FIGO World Congress of Gynecology and Obstetrics"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.fertnstert.2006.07.366","article-title":"Intravenous hydroxyethyl starch versus human albumin for prevention of the ovarian hyperstimulation syndrome","volume":"86 Suppl 2","author":"Fan","year":"2006","journal-title":"Fertility and Sterility"},{"issue":"4","key":"10.1002\/14651858.CD001302.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0015-0282(99)00606-8","article-title":"An ounce of prevention: outpatient management of the ovarian hyperstimulation syndrome","volume":"73","author":"Fluker","year":"2000","journal-title":"Fertility and Sterility"},{"issue":"6","key":"10.1002\/14651858.CD001302.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/S0015-0282(02)03088-1","article-title":"Comparative efficacy of hydroxyethyl starch and Haemaccel for the treatment of severe ovarian hyperstimulation syndrome","volume":"77","author":"Gamzu","year":"2002","journal-title":"Fertility and Sterility"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD001302.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.fertnstert.2005.07.804","article-title":"A randomized prospective placebo-controlled study of intravenous albumin vs. hydroxyethyl starch for the prevention of ovarian hyperstimulation in an in-vitro fertilization programme","volume":"84","author":"Gokmen","year":"2005","journal-title":"Fertility and Sterility: Abstracts of ASRM"},{"issue":"12","key":"10.1002\/14651858.CD001302.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1093\/humrep\/12.12.2599","article-title":"Reduced incidence of ovarian hyperstimulation syndrome by prophylactic infusion of hydroxyethyl starch solution in an in-vitro fertilization programme","volume":"12","author":"Graf","year":"1997","journal-title":"Human Reproduction"},{"issue":"4","key":"10.1002\/14651858.CD001302.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0015-0282(16)57866-2","article-title":"A case of severe ovarian hyperstimulation in a healthy oocyte donor","volume":"64","author":"Halme","year":"1995","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0032|cit32","first-page":"238","article-title":"Intravenous albumin combined with low dose human chorionic gonadotrophin and late step-down administration of menotropins are effective in prevention of severe ovarian hyperstimulation syndrome in high-risk patients in an in vitro fertilisation program","volume":"2\/3","author":"Isik","year":"1997","journal-title":"Middle East Fertility Society Journal"},{"issue":"2","key":"10.1002\/14651858.CD001302.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0301-2115(00)00539-X","article-title":"Combined approach as an effective method in the prevention of severe ovarian hyperstimulation syndrome","volume":"97","author":"Isik","year":"2001","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0301-2115(01)00364-5","article-title":"The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation syndrome: a case report","volume":"99","author":"Kissler","year":"2001","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1093\/humrep\/15.1.113","article-title":"Clinical efficacy of peritoneovenous shunting for the treatment of sever ovarian hyperstimulation syndrome","volume":"15","author":"Koike","year":"2000","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.fertnstert.2005.07.686","article-title":"Intravenous albumin prophylaxis in high risk patients for moderate to severe ovarian hyperstimulation syndrome","volume":"84 Suppl","author":"Kumbak","year":"2005","journal-title":"Fertility and Sterility"},{"issue":"4","key":"10.1002\/14651858.CD001302.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0015-0282(16)58584-7","article-title":"Does intravenous administration of human albumin prevent severe ovarian hyperstimulation syndrome?","volume":"66","author":"Lewit","year":"1996","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1014828027282","article-title":"Aggressive outpatient treatment of ovarian hyperstimulation syndrome with ascites using transvaginal culdocentesis and intravenous albumin minimizes hospitalization","volume":"19","author":"Lincoln","year":"2002","journal-title":"Journal of Assisted Reproduction and Genetics"},{"issue":"2","key":"10.1002\/14651858.CD001302.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejogrb.2013.07.010","article-title":"Prevention of ovarian hyperstimulation syndrome in GnRH agonist IVF cycles in moderate risk patients: randomized study comparing hydroxyethyl starch versus cabergoline and hydroxyethyl starch","volume":"170","author":"Matorras","year":"2013","journal-title":"European Journal of Obstetrics Gynecology and Reproductive Biology"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0040|cit40","first-page":"216","article-title":"Prevention of ovarian hyperstimulation syndrome with iv albumin","volume":"11","author":"Milacic","year":"1996","journal-title":"Human Reproduction"},{"issue":"3","key":"10.1002\/14651858.CD001302.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0015-0282(16)57806-6","article-title":"Severe ovarian hyperstimulation despite prophylactic albumin at the time of oocyte retrieval for in vitro fertilization and embryo transfer","volume":"64","author":"Mukherjee","year":"1995","journal-title":"Fertility and Sterility"},{"issue":"4","key":"10.1002\/14651858.CD001302.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"248","DOI":"10.4103\/0974-1208.126293","article-title":"Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome","volume":"6","author":"Naredi","year":"2013","journal-title":"Journal of Human Reproductive Sciences"},{"issue":"5","key":"10.1002\/14651858.CD001302.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/S0015-0282(97)00364-6","article-title":"Severe ovarian hyperstimulation syndrome: is it really preventable by prophylactic intravenous albumin?","volume":"68","author":"Ndukwe","year":"1997","journal-title":"Fertility and Sterility"},{"issue":"4","key":"10.1002\/14651858.CD001302.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/oxfordjournals.humrep.a136043","article-title":"Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome in an in-vitro fertilization programme","volume":"10","author":"Ng","year":"1995","journal-title":"Human Reproduction"},{"issue":"2","key":"10.1002\/14651858.CD001302.pub3-BIB0045|cit45","first-page":"179","article-title":"Does the prophylactic use of intravenous albumin prevent ovarian hyperstimulation syndrome? A randomised prospective study","volume":"2","author":"Iammarone","year":"1999","journal-title":"Human Fertility"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0046|cit46","first-page":"105","article-title":"Does the prophylactic use of intravenous albumin prevent ovarian hyperstimulation syndrome? A randomized prospective study","volume":"14","author":"Panay","year":"1999","journal-title":"Abstracts from the 15th Annual Meeting of the ESHRE, Tours, France"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/S0015-0282(16)58275-2","article-title":"Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian of ovarian hyperstimulation syndrome","volume":"65","author":"Shaker","year":"1996","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0015-0282(16)55223-6","article-title":"The administration of glucocorticoids for the prevention of ovarian hyperstimulation syndrome in invitro fertilisation: a prospective randomised study","volume":"58","author":"Tan","year":"1992","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD001302.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s10815-011-9708-4","article-title":"Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trial.","volume":"29","author":"Tehraninejad","year":"2012","journal-title":"Journal of Assisted Reproduction & Genetics."},{"issue":"10","key":"10.1002\/14651858.CD001302.pub3-BIB0050|cit50","first-page":"837","article-title":"Comparison of albumin and cabergoline in the prevention of ovarian hyperstimulation syndrome: A clinical trial study.","volume":"11","author":"Torabizadeh","year":"2013","journal-title":"Iranian Journal of Reproductive Medicine"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0051|cit51","first-page":"s20","article-title":"Intravenous administration of calcium in ovarian hyperstimulation syndrome (OHSS) prevention","volume":"1","author":"Yakovenko","year":"2011","journal-title":"European Journal of Obstetrics Gynecology and Reproductive Biology"},{"issue":"3","key":"10.1002\/14651858.CD001302.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/humupd\/dmg018","article-title":"Ovarian hyperstimulation syndrome: classifications and critical analysis of preventive measures","volume":"9","author":"Aboulghar","year":"2003","journal-title":"Human Reproduction Update"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0053|cit53","first-page":"i60","article-title":"Differential regulation of VEGF, Cadherin, and Angiopietin 2 by trigger oocyte maturation with GnRHa vs hCG in donors: try to explain the lower OHSS incidence","volume":"24","author":"Cerrillo","year":"2009","journal-title":"Abstracts of the 25th\u00a0 annual meeting of the ESHRE"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1472-6483(10)61727-0","article-title":"Ovarian hyperstimulation syndrome: strategies for prevention","volume":"7","author":"Chen","year":"2003","journal-title":"Reproductive Biomedicine Online"},{"issue":"3","key":"10.1002\/14651858.CD001302.pub3-BIB0055|cit55","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002806.pub2","article-title":"Embryo freezing for preventing ovarian hyperstimulation syndrome","author":"D'Angelo","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD001302.pub3-BIB0056|cit56","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002811.pub3","article-title":"Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome","author":"D'Angelo","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/humupd\/8.6.559","article-title":"Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review","volume":"8","author":"Delvigne","year":"2002","journal-title":"Human Reproduction Update"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1472-6483(10)60699-2","article-title":"IVF, IVM, natural cycle IVF, minimal stimulation IVF - time for a rethink","volume":"15","author":"Edwards","year":"2007","journal-title":"Reproductive Biomedicine Online"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/humrep\/15.1.8","article-title":"Severe OHSS: how many cases are preventable?","volume":"15","author":"Egbase","year":"2000","journal-title":"Human Reproduction"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.fertnstert.2007.02.002","article-title":"The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomised controlled study","volume":"89","author":"Engmann","year":"2008","journal-title":"Fertility and Sterility"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0301-2115(00)00460-7","article-title":"Plasma levels of free vascular endothelial growth factor(165) (VEGF(165)) are not elevated during gonadotropin stimulation in in vitro fertilization (IVF) patients developing ovarian hyperstimulation syndrome (OHSS): results of a prospective cohort study with matched controls","volume":"96","author":"Enskog","year":"2001","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"issue":"6","key":"10.1002\/14651858.CD001302.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0015-0282(02)04392-3","article-title":"Ovarian hyperstimulation syndrome is associated with reversible impairment of vascular reactivity","volume":"78","author":"Foong","year":"2002","journal-title":"Fertility and Sterility"},{"issue":"3","key":"10.1002\/14651858.CD001302.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00001703-200306000-00007","article-title":"New concepts in the understanding of the ovarian hyperstimulation syndrome","volume":"15","author":"Garcia-Velasco","year":"2003","journal-title":"Current Opinion in Obstetrics and Gynecology"},{"issue":"6","key":"10.1002\/14651858.CD001302.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/00006254-198906000-00004","article-title":"Ovarian hyperstimulation syndrome: an update review","volume":"44","author":"Golan","year":"1989","journal-title":"Obstetrical & Gynecological Survey"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0065|cit65","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] The Cochrane Collaboration 2011"},{"issue":"2","key":"10.1002\/14651858.CD001302.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"389-400","DOI":"10.1016\/j.fertnstert.2010.03.028","article-title":"Preventing ovarian hyperstimulation syndrome: guidance for the clinician","volume":"94","author":"Humaidan","year":"2010","journal-title":"Fertility and Sterility"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"47-54. Epub 201","DOI":"10.1159\/000286379","article-title":"Administration of intravenous albumin around the time of oocyte retrieval reduces pregnancy rate without preventing ovarian hyperstimulation syndrome: a systematic review and meta-analysis","volume":"70","author":"Jee","year":"2010","journal-title":"Gynecologic and Obstetric Investigation"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10815-008-9198-1","article-title":"GnRH agonist for triggering final oocyte maturation in patients at risk of ovarian hyperstimulation syndrome: still a controversy?","volume":"25","author":"Kol","year":"2008","journal-title":"Journal of Assisted Reproduction and Genetics"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1196\/annals.1365.020","article-title":"Oocyte maturation in assisted reproductive techniques","volume":"1092","author":"Loutradis","year":"2006","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1471-0528.2000.tb10393.x","article-title":"Is ovarian hyperstimulation syndrome associated with a poor obstetric outcome?","volume":"107","author":"Mathur","year":"2000","journal-title":"BJOG"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1136\/bmj.300.6716.35","article-title":"Human albumin solutions","volume":"300","author":"McClelland","year":"1990","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0002-9378(88)90523-6","article-title":"Risk factors and prognostic variables in the ovarian hyperstimulation syndrome","volume":"159","author":"Navot","year":"1988","journal-title":"American Journal of Obstetrics and Gynecology"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0015-0282(16)55188-7","article-title":"Ovarian hyperstimulation syndrome in novel reproductive technologies:prevention and treatment","volume":"58","author":"Navot","year":"1992","journal-title":"Fertility & Sterility"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/humupd\/3.3.255","article-title":"The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome","volume":"3","author":"Rizk","year":"1997","journal-title":"Human Reproduction Update"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0075|cit75","first-page":"131","article-title":"Classification, pathophysiology and management of ovarian hyperstimulation syndrome","volume-title":"In-Vitro Fertilization and Assisted Reproduction","author":"Rizk","year":"1999"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0076|cit76","first-page":"225","article-title":"Ovarian hyperstimulation syndrome: a current survey","volume":"30","author":"Schenker","year":"1978","journal-title":"Fertility and Sterility"},{"issue":"2","key":"10.1002\/14651858.CD001302.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1093\/bjaceaccp\/mkr063","article-title":"Mannitol: a review of its clinical uses","volume":"12","author":"Shawkat","year":"2012","journal-title":"Continuing Education in Anaesthesia, Critical Care & Pain"},{"issue":"2","key":"10.1002\/14651858.CD001302.pub3-BIB0078|cit78","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008605.pub2","article-title":"Cabergoline for preventing ovarian hyperstimulation syndrome","author":"Tang","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD001302.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.fertnstert.2010.05.026","article-title":"Intravenous albumin administration for the prevention of severe ovarian hyperstimulation syndrome: a systematic review and metaanalysis","volume":"95","author":"Venetis","year":"2011","journal-title":"Fertility and Sterilility"},{"issue":"5","key":"10.1002\/14651858.CD001302.pub3-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bpobgyn.2009.02.006","article-title":"Ovarianhyperstimulation syndrome and complications of ART","volume":"23","author":"Vloeberghs","year":"2009","journal-title":"Best Practice & Research. Clinical Obstetrics & Gynaecology"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0081|cit81","unstructured":"WHO Agents stimulating gonadal function in human World Health Organization Technical Report Series 1973 514 20"},{"key":"10.1002\/14651858.CD001302.pub3-BIB0082|cit82","first-page":"1723","article-title":"Ascular endothelial growth factor (VEGF) messenger ribonucleic acid (mRNA) expression in luteinized human granulosa cells in vitro","volume":"77","author":"Yan","year":"1993","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"issue":"10","key":"10.1002\/14651858.CD001302.pub3-BIB0083|cit83","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008046.pub4","article-title":"Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology","author":"Youssef","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001302.pub3-BIB0084|cit84","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001302","article-title":"Intra-venous fluids preventing severe ovarian hyperstimulation syndrome","author":"Youssef","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001302.pub3-BIB0085|cit85","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001302.pub2","article-title":"Intra-venous fluids for the prevention of severe ovarian hyperstimulation syndrome","author":"Youssef","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD001302.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T07:18:20Z","timestamp":1656573500000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001302.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecology and Fertility Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,31]]},"references-count":85,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001302.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,31]]}}}